A review of 135,000 patients with atrial fibrillation led to over 25,000 medical interventions, prevented hundreds of strokes and saved the NHS millions of pounds.

Verseon’s new class of anticoagulants are part of a growing portfolio of drug programs being developed with the aid of the Company’s proprietary, computational drug discovery platform

MR Solutions brings new 3D, 1000 X magnification imaging modality to preclinical research